After all the noise they made, there would certainly be a lot of questions asked (if they raised their bid).
Boston Scientific will do everything in its power to reach a deal with Guidant.
But that is an awfully long time to look out for pharmaceuticals.
I certainly think it could be a stand-alone company. I'm not certain it should be.
I don't believe these things are going to matter for Boston Scientific. This is a strategic deal for them and these are small perturbations along the way.
I don't think it's a sure thing by any stretch, but I think they have a good chance of making it.
I don't think there's much risk to employees ? especially the Minnesota contingent.
I have a feeling that Temecula is pretty safe.
I haven't heard from a single Guidant shareholder who doesn't like the Boston Scientific deal.
I think investors do take insider buying as a good sign, and I think they especially wanted Boston Scientific to do it.
I think it's an amazing turn of events.
I think of all the pieces, it's pharmaceuticals that are hurting them the most.
I think there are some actions the company will have to take and some expenses the company will have to incur that will make it tough. I still think given those parameters, it can be, stay and remain an independent company and eventually flourish.
I think they (St. Jude) definitely look like they are in play. They certainly would be an attractive candidate.
Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.
Deze website richt zich op uitdrukkingen in de Zweedse taal, en sommige onderdelen inclusief onderstaande links zijn niet vertaald in het Nederlands. Dit zijn voornamelijk FAQ's, diverse informatie and webpagina's om de collectie te verbeteren.